Detail akcie Delcath Sys Rg online

Business Summary: Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
Financial Summary: BRIEF: For the three months ended 31 March 2025, Delcath Systems Inc revenues increased from $3.1M to $19.8M. Net income totaled $1.1M vs. loss of $11.1M. Revenues reflect HEPZATO KIT segment increase from $2M to $18M, CHEMOSAT segment increase of 56% to $1.8M. Net Income reflects Change in fair value of warrant liabilit decrease from $612K (expense) to $0K, Other income (expense) increase from $22K (expense) to $4K (income).